The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Matilde Saggese
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Alastair Mathewson
Employment or Leadership Position - AstraZeneca
Charlotte Rose Lemech
No relevant relationships to disclose
Donal Landers
Employment or Leadership Position - AstraZeneca
Paul Frewer
Employment or Leadership Position - AstraZeneca
Elaine Kilgour
Employment or Leadership Position - AstraZeneca
Nigel Brooks
Employment or Leadership Position - AstraZeneca